Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Quarterly results
Inv. presentation
Asset disposition
|
|
RAPT Therapeutics, Inc. (RAPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/14/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “This progress has positioned us ...",
"29 8 15 43" |
|
| 01/09/2023 |
8-K
| Investor presentation |
| 09/06/2022 |
8-K
| Investor presentation |
| 09/27/2021 |
8-K
| Investor presentation |
| 01/09/2020 |
8-K
| Investor presentation |
|
|